Drug intelligence / Profile preview

JWK008

Development stage: Unknown
Lead developer: Genevector
Modality: Small Molecules
Administration: Intravenous

Overview

JWK008 is a small molecule agonist of Toll-like receptor 7 (TLR7) developed by Jingwukang (Beijing) Pharmaceutical Technology. By targeting TLR7, which is primarily expressed on plasmacytoid dendritic cells (pDCs) and B cells, JWK008 stimulates the innate immune system to produce Type I interferons (IFN-α) and other pro-inflammatory cytokines. This activation enhances the maturation and antigen-presenting capacity of dendritic cells, subsequently promoting the activation and proliferation of cytotoxic T lymphocytes and natural killer (NK) cells to generate a potent anti-tumor immune response. JWK008 is currently in Phase 1 clinical development for the treatment of advanced solid tumors, where it is administered via intravenous infusion.

Other names: JWK008JWK-008JWK 008

Targets

IDUA (Alpha-L-iduronidase)

Beyond the preview

Go deeper on JWK008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JWK008.

Explore the full profile